Photo by Sharon McCutcheon on Pexels.com

Planet Green Holdings Stock Rose 331% Fueled By $10-Million Deal and Blue Gem

Planet Green Holdings Stock Rose 331 Percent Fueled by $50-Million Acquisition of 17.9 Blue Gem

By Glenford S. Robinson

Talk about a hyperbolic launch into space, Planet Green Holdings Corp. (NYSE: PLAG) did just that with its climactic rise into the stratosphere of 331% on Friday, launching from a day’s low of $2.85 to $11.51, with a trading volume of about 5.8 million shares as of 10:18 a.m. ET, compared with a 65-day average volume of 60,378.

So, what has caused such an amazing run? Well, it all comes down to the press release the company released on October 16, 2018. According to Benzinga, another reason for the climactic rise of PLAG is that Yulong Eco-Materials Ltd. (NASDAQ: YECO) rose more than 600 percent this past week after the company announced a $50-million acquisition deal for the millennium Sapphire, a 17.9 blue gem that was recently appraised at a value between $60 million and $90 million.

As a result of this deal, Yulong said it has decided to begin the process of spinning off its China business by moving its headquarters to New York, so the company can focus on its gemstone business. In addition, this Yulong news seemed to have drawn an increased amounts of trading volume into other U.S.-listed Chinese stocks, such as TDH Holdings (NASDAQ:PETZ), which rose 40.9 percent.

The press release stated that PLAG closed a private placement transaction deal with Yimin Jin, the Company’s chief strategy officer and director, and Hongxiang Yu, the company’s chairman.

The company received $10 million in exchange for 2.4 million shares of the company’s common stock, which represents a purchase price of approximately $4.25 per share. It was at the Company’s 2018 annual shareholders meeting that the transaction received approval.

Trading of the company’s stock (PLAG) is currently halted due to pending news and the anticipation of extremely high volatility at the time of writing this article (1:00 pm-2:41pm, ET; Friday, October 18, 2018.

Anyone wishing to trade this dangerous stock should consult with his or her own investment advisor.

© 2018 mstardom.com. Mstardom Finance does not provide investment advice. All rights reserved

Check Also

Litigation Photo

Immune Design (IMDZ) Alert: Johnson Fistel Investigates Proposed Sale of Immune Design Corp.; Are Immune Design Shareholders Getting a Fair Deal?

The investigation concerns whether the Immune Design board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Immune Design shares of common stock. Nationally recognized Johnson Fistel is investigating whether the proposed deal represents adequate consideration, especially given that one Wall Street analyst has a $9.00 price target on the stock and the Company has approximately $100 million in cash and no long-term debt.

Mergers and Acquisitions

Merck to Acquire Immune Design; Acquisition Bolsters Capabilities in Vaccine Development for Infectious Diseases and Cancer

“Scientists at Immune Design have established a unique portfolio of approaches to cancer immunization and adjuvant systems designed to enhance the ability of a vaccine to protect against infection, which could meaningfully improve vaccine development," said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. “This acquisition builds upon Merck’s industry-leading programs that harness the power of the immune system to prevent and treat disease.”

SEC Files Charges in Elaborate Microcap Stock Fraud

“As alleged in our complaint, Magna Group and its co-defendants used fake debt instruments to unlawfully obtain shares in microcap companies, which they then dumped on unsuspecting retail investors,” said Sanjay Wadhwa, Senior Associate Director of the SEC’s New York Regional Office. “This action demonstrates the resolve of the SEC in pursuing fraudsters who use elaborate financing schemes to engage in securities fraud.”

Investor Alert and Bulletin From SEC Office of Investor Education and Advocacy

Know how to be a better investor. Did you know that active trading and some other very common investing behaviors actually can undermine investment performance? According to researchers, other common investing mistakes include focusing on past performance, favoring investments from your own country, region, state, or company, and holding on to losing investments too long and selling winning investments too soon.

COURT ORDERS $1 BILLION JUDGMENT AGAINST OPERATORS OF WOODBRIDGE PONZI SCHEME TARGETING RETAIL INVESTORS

"This resolution accomplishes one of the SEC's core missions to protect retail investors," said Stephanie Avakian, Co-Director of the SEC's Division of Enforcement. "Mr. Shapiro and other defendants will be held accountable and required to pay substantial penalties for their misconduct." "Our complaint charged that when Woodbridge's fictitious business model collapsed, the company stopped paying investors and filed for Chapter 11 bankruptcy protection," said Eric I. Bustillo, Director of the SEC's Miami Regional Office. "The settlement provides for the return of significant funds to investors."

SEC Charges Cognizant and Two Former Executives With FCPA Violations

“Bribery to further corporate goals is an illusory path to long-term success. While always the wrong choice, it is particularly egregious when senior executives chart that course for those they lead, as our complaint alleges here. We are committed to holding them accountable for their actions,” said Charles E. Cain, Chief of the SEC Enforcement Division’s FCPA Unit.

FDA Authorizes First Interoperable Insulin Pump Intended to Allow Patients to Customize Treatment Through their Individual Diabetes Management Devices

“Diabetes is a complicated disease that requires close monitoring and carefully tailored treatments. We’ve heard from the patient community that having the ability to customize their own diabetes management devices is important to them. Advances in digital health make more tailored approaches to diabetes care possible,” said FDA Commissioner Scott Gottlieb, M.D. “The marketing authorization of the first ACE insulin pump intended for interoperable use has the potential to aid patients who seek more individualized diabetes therapy systems and opens the door for developers of future connected diabetes devices to get other safe and effective products to patients more efficiently. Because the FDA’s action creates a new regulatory classification, future ACE insulin pumps will be able to go through the more efficient 510(k) review process, helping to advance this innovative technology. We’re committed to advancing new ways to accelerate the development of innovations that can improve patient care while strengthening our pre- and post-market tools for determining the safety and effectiveness of these new technologies.

%d bloggers like this: